5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Skeletal O
muscle O
effects O
( O
e.g. O
, O
myopathy O
and O
rhabdomyolysis O
) O
: O
Risks O
increase O
in O
a O
dose-dependent O
manner O
, O
with O
advanced O
age O
( O
> O
=65 O
) O
, O
renal O
impairment O
, O
and O
inadequately O
treated O
hypothyroidism O
. O

Advise O
patients O
to O
promptly O
report O
unexplained O
and/or O
persistent O
muscle O
pain O
, O
tenderness O
, O
or O
weakness O
, O
and O
discontinue O
LIVALO O
( O
5.1 O
) O
* O
Liver O
enzyme O
abnormalities O
: O
Persistent O
elevations O
in O
hepatic O
transaminases O
can O
occur O
. O

Check O
liver O
enzyme O
tests O
before O
initiating O
therapy O
and O
as O
clinically O
indicated O
thereafter O
( O
5.2 O
) O
5.1 O
Skeletal O
Muscle O
Effects O
Cases O
of O
myopathy B-OSE_Labeled_AE
and O
rhabdomyolysis B-OSE_Labeled_AE
with O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
secondary O
to O
myoglobinuria B-OSE_Labeled_AE
have O
been O
reported O
with O
HMG-CoA O
reductase O
inhibitors O
, O
including O
LIVALO O
. O

These O
risks O
can O
occur O
at O
any O
dose O
level O
, O
but O
increase O
in O
a O
dose-dependent O
manner O
. O

LIVALO O
should O
be O
prescribed O
with O
caution O
in O
patients O
with O
predisposing O
factors O
for O
myopathy B-NonOSE_AE
. O

These O
factors O
include O
advanced O
age O
( O
> O
=65 O
years O
) O
, O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
and O
inadequately O
treated O
hypothyroidism B-Not_AE_Candidate
. O

The O
risk O
of O
myopathy B-NonOSE_AE
may O
also O
be O
increased O
with O
concurrent O
administration O
of O
fibrates O
or O
lipid-modifying O
doses O
of O
niacin O
. O

LIVALO O
should O
be O
administered O
with O
caution O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
in O
elderly O
patients O
, O
or O
when O
used O
concomitantly O
with O
fibrates O
or O
lipid-modifying O
doses O
of O
niacin O
[ O
see O
Drug O
Interactions O
( O
7.6 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
, O
8.6 O
) O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Cases O
of O
myopathy B-NonOSE_AE
, O
including O
rhabdomyolysis B-NonOSE_AE
, O
have O
been O
reported O
with O
HMG-CoA O
reductase O
inhibitors O
coadministered O
with O
colchicine O
, O
and O
caution O
should O
be O
exercised O
when O
prescribing O
LIVALO O
with O
colchicine O
[ O
see O
Drug O
Interactions O
( O
7.7 O
) O
] O
. O

There O
have O
been O
rare O
reports O
of O
immune B-OSE_Labeled_AE
- I-OSE_Labeled_AE
mediated I-OSE_Labeled_AE
necrotizing I-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
IMNM I-OSE_Labeled_AE
) O
, O
an O
autoimmune B-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
, O
associated O
with O
statin O
use O
. O

IMNM B-NonOSE_AE
is O
characterized O
by O
: O
proximal B-NonOSE_AE
muscle I-NonOSE_AE
weakness I-NonOSE_AE
and O
elevated B-NonOSE_AE
serum I-NonOSE_AE
creatine I-NonOSE_AE
kinase I-NonOSE_AE
, O
which O
persist O
despite O
discontinuation O
of O
statin O
treatment O
; O
muscle O
biopsy O
showing O
necrotizing B-NonOSE_AE
myopathy I-NonOSE_AE
without O
significant O
inflammation B-NonOSE_AE
; O
improvement O
with O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
. O

LIVALO O
therapy O
should O
be O
discontinued O
if O
markedly O
elevated B-NonOSE_AE
creatine I-NonOSE_AE
kinase I-NonOSE_AE
( I-NonOSE_AE
CK I-NonOSE_AE
) O
levels O
occur O
or O
myopathy B-NonOSE_AE
is O
diagnosed O
or O
suspected O
. O

LIVALO O
therapy O
should O
also O
be O
temporarily O
withheld O
in O
any O
patient O
with O
an O
acute O
, O
serious O
condition O
suggestive O
of O
myopathy B-NonOSE_AE
or O
predisposing O
to O
the O
development O
of O
renal B-NonOSE_AE
failure I-NonOSE_AE
secondary O
to O
rhabdomyolysis B-NonOSE_AE
( O
e.g. O
, O
sepsis B-Not_AE_Candidate
, O
hypotension B-Not_AE_Candidate
, O
dehydration B-Not_AE_Candidate
, O
major O
surgery O
, O
trauma O
, O
severe B-Not_AE_Candidate
metabolic I-Not_AE_Candidate
, O
endocrine O
, O
and O
electrolyte O
disorders I-Not_AE_Candidate
, O
or O
uncontrolled O
seizures B-Not_AE_Candidate
) O
. O

All O
patients O
should O
be O
advised O
to O
promptly O
report O
unexplained O
muscle B-NonOSE_AE
pain I-NonOSE_AE
, O
tenderness B-NonOSE_AE
, O
or O
weakness B-NonOSE_AE
, O
particularly O
if O
accompanied O
by O
malaise B-NonOSE_AE
or O
fever B-NonOSE_AE
or O
if O
muscle B-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
persist O
after O
discontinuing O
LIVALO O
. O

5.2 O
Liver O
Enzyme O
Abnormalities O
Increases B-OSE_Labeled_AE
in O
serum I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
( O
aspartate O
aminotransferase O
[ O
AST O
] O
/serum O
glutamic-oxaloacetic O
transaminase O
, O
or O
alanine O
aminotransferase O
[ O
ALT O
] O
/serum O
glutamic-pyruvic O
transaminase O
) O
have O
been O
reported O
with O
HMG-CoA O
reductase O
inhibitors O
, O
including O
LIVALO O
. O

In O
most O
cases O
, O
the O
elevations O
were O
transient O
and O
resolved O
or O
improved O
on O
continued O
therapy O
or O
after O
a O
brief O
interruption O
in O
therapy O
. O

In O
placebo-controlled O
Phase O
2 O
studies O
, O
ALT B-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
times I-NonOSE_AE
the I-NonOSE_AE
upper I-NonOSE_AE
limit I-NonOSE_AE
of I-NonOSE_AE
normal I-NonOSE_AE
was O
not O
observed O
in O
the O
placebo O
, O
LIVALO O
1 O
mg O
, O
or O
LIVALO O
2 O
mg O
groups O
. O

One O
out O
of O
202 O
patients O
( O
0.5 O
% O
) O
administered O
LIVALO O
4 O
mg O
had O
ALT B-OSE_Labeled_AE
> I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
. O

It O
is O
recommended O
that O
liver O
enzyme O
tests O
be O
performed O
before O
the O
initiation O
of O
LIVALO O
and O
if O
signs O
or O
symptoms O
of O
liver B-NonOSE_AE
injury I-NonOSE_AE
occur O
. O

There O
have O
been O
rare O
postmarketing O
reports O
of O
fatal B-NonOSE_AE
and O
non-fatal O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
patients O
taking O
statins O
, O
including O
pitavastatin O
. O

If O
serious O
liver B-NonOSE_AE
injury I-NonOSE_AE
with O
clinical O
symptoms O
and/or O
hyperbilirubinemia B-NonOSE_AE
or O
jaundice B-NonOSE_AE
occurs O
during O
treatment O
with O
LIVALO O
, O
promptly O
interrupt O
therapy O
. O

If O
an O
alternate O
etiology O
is O
not O
found O
do O
not O
restart O
LIVALO O
. O

As O
with O
other O
HMG-CoA O
reductase O
inhibitors O
, O
LIVALO O
should O
be O
used O
with O
caution O
in O
patients O
who O
consume O
substantial O
quantities O
of O
alcohol O
. O

Active O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
which O
may O
include O
unexplained O
persistent O
transaminase B-Not_AE_Candidate
elevations I-Not_AE_Candidate
, O
is O
a O
contraindication O
to O
the O
use O
of O
LIVALO O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.3 O
Endocrine O
Function O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
HbA I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
and O
fasting O
serum O
glucose O
levels O
have O
been O
reported O
with O
HMG-CoA O
reductase O
inhibitors O
, O
including O
LIVALO O
. O

